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Abstract 
There is an urgent need for accurate biomarkers of disease. The low-molecular 
weight proteome of blood serum or other biological fluids may be an ideal source of 
such biomarkers, although its analysis requires high-throughput strategies to enrich 
and quantify peptides and small proteins with biomarker potential. Herein, serum 
samples from cancer cases and controls are compared using a workflow of robotic 
reversed-phase extraction and clean-up, followed by automated MALDI MS spectral 
acquisition and analysis of the low-molecular weight peptidome. The aim of the 
presented methodology is to facilitate the discovery of candidate serum biomarkers 
of cancer using MALDI MS profiling, although the method is applicable to any 
comparative proteomic analysis of any biofluid. 
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1. Introduction 
There is an urgent need for accurate disease biomarkers, which may provide 
novel approaches to diagnosis and screening. The blood serum/plasma proteome 
may be an ideal source of such biomarkers, although its complexity necessitates 
novel strategies to enrich and quantify low-abundance protein species with 
biomarker potential. The low-molecular weight proteome or ‘peptidome’ of 
serum/plasma is also a source of potential disease biomarkers (Geho et al. 2006; 
Hortin 2006; Liotta and Petricoin 2006; Petricoin et al. 2006; Villanueva et al. 2006a). 
Low-molecular weight proteins and peptides occur endogenously within the 
bloodstream, whilst protein fragments may be derived in vivo or ex vivo through the 
action of proteases on both blood-borne and cell/tissue-derived proteins. Both 
MALDI and its derivative SELDI MS are well-suited for profiling the peptidome of 
biofluids and are particularly suited for high-throughput analyses, i.e. profiling of 
100s or 1000s of samples in a single experiment. For comparative analyses in 
biomarker discovery, peptide peak intensities (peak areas or heights) from spectra 
acquired from multiple samples are compared between different clinical and control 
groups using dedicated analysis software tools. Differences in peak intensities are 
typically reported as ratios between the groups with an associated statistic to 
evaluate the significance of any differences. Since the comparisons are multivariate, 
correction for multiple testing must be applied. Any peaks of interest must then be 
identified, usually using orthogonal methods such as tandem MS or antibody-based 
methods. The onus is on proving that a peak identified by such methods is exactly 
the same species as the differential peak identified from the (MALDI) MS profiling. 
This is not always trivial, particularly given the lower mass accuracy of typical 
MALDI time-of-flight (TOF) instruments. Ideally, tandem MS identification is 
performed within the same experiment as the profiling. 
Much criticism has been levelled at low-molecular weight serum/plasma profiling 
for biomarker discovery using MALDI and SELDI MS (Diamandis 2004a, 2006; 
Davis et al. 2010). This largely concerns experimental bias introduced during pre-
analytical sample handling. It is without doubt the case that proteolysis has a huge 
influence on the peptidome patterns of biofluids, particularly serum. Any difference 
in handling (e.g. clotting time, temperature, storage etc.) between samples may 
affect proteolysis and has been shown to influence the resulting peptidome patterns 
(Karsan et al. 2005; Banks et al. 2005; Timms et al. 2007; Baggerly et al. 2004). 
Essentially, this gives rise to technical variation that can mask true biological 
variation and increase the false positive rate. Thus, in any profiling study it must be 
ensured that all samples are collected, handled and stored as identically as possible 
to avoid such bias. Concerns have also been raised over assay reproducibility and 
the robustness of class-discriminating algorithms used for MALDI MS profiling 
biomarker discovery (Diamandis 2004b; Baggerly et al. 2005). Thus, monitoring and 
reporting of platform reproducibility is obligatory, whilst the robustness of algorithms 
must be assessed through proper training and test set validation. Finally, it has been 
argued that these high-throughput methods lack the sensitivity to detect low-
abundance species, with coverage limited to abundant small proteins and fragments 
of coagulation proteins. This appears to be the case as evidenced by identifications 
assigned to MALDI MS spectral peaks recorded from serum samples, where 
fibrinogen fragments were the predominant species (Tiss et al. 2010). However, this 
is not to say that these small proteins, endogenous peptides or proteolytic fragments 
do not have potential as disease biomarkers as many seemingly well-controlled 
studies have reported. Indeed, it has been proposed that fragments of abundant 
coagulation proteins are surrogate peptide markers of cancer, generated ex vivo 
during coagulation through the action of tumour-specific exopeptidases (Villanueva 
et al. 2006c). This may also hold true in other diseases, where low-abundance, 
disease-associated proteases may generate specific patterns of protein fragments 
with diagnostic potential. 
  
2. Applications 
Herein, we describe a reproducible, high-throughput, semi-automated, MALDI 
MS profiling method similar to that used in (Timms et al. 2010) (see Figure 1). The 
method describes the profiling of serum from case control sample sets, although it is 
equally applicable to other biological fluids/clinical specimens such as plasma, 
cerebrospinal fluid, urine, ascites and saliva. We also describe the data analysis 
steps and a protocol for identification of discriminatory peaks with biomarker 
potential. The aim of the presented methodology is to facilitate the discovery of 
candidate serum biomarkers for the differential diagnosis of ovarian cancer. 
This protocol and a slight variation of it with regard to the serum peptide 
extraction step (Tiss et al. 2007) have been used for biomarker discovery studies for 
the early detection of ovarian cancer (Timms et al. 2010; Timms et al. 2011) and 
differential diagnosis of biliary tract cancer (Sandanayake et al. 2014). Similar 
protocols have been used by other groups for diagnostic biomarker discovery in a 
variety of cancers (Villanueva et al. 2006b; Villanueva et al. 2006c; Pietrowska et al. 
2009) and other diseases/infections (Conraux et al. 2013; Li et al. 2012; Terracciano 
et al. 2011; Teunissen et al. 2011; Xiao et al. 2011), for predictive and prognostic 
biomarker discovery (Vafadar-Isfahani et al. 2010; Taguchi et al. 2007), and to 
identify blood-borne markers of ageing (Lu et al. 2012). 
 Figure 1:  Schematic workflow for MALDI MS profiling of biofluids 
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3. Materials and Protocols 
3.1. Materials 
3.1.1. Serum collection and storage 
1. 8.5-mL BD Vacutainer® SST™ Advance Tubes (Becton Dickinson 
Diagnostics, New Jersey, US). 
2. Bench top centrifuge. 
3. Cryovials. 
4. -80°C freezer. 
5. Quality control human serum (cat. no.: H4522; Sigma-Aldrich Company Ltd, 
Dorset, UK). 
 
3.1.2. Serum polypeptide extraction and sample preparation 
1. 96-well Star PCR raised rim skirted plates (Starlab UK Ltd, Milton Keynes, 
UK). 
2. RPC18 Dynabeads (Invitrogen Ltd, Paisley, UK)1. 
3. 96-well magnetic bead separator (Bruker UK, Coventry, UK). 
4. Trifluoroacetic acid (TFA; 100% HPLC grade; Rathburn Chemicals Ltd, 
Walkerburn, Scotland). 
5. Acetonitrile (ACN; 100% HPLC grade; Rathburn Chemicals Ltd). 
6. Methanol. 
7. Genesis Freedom 200 liquid-handling work station (Tecan UK Ltd, Reading, 
UK). 
8. α-Cyano-4-hydroxycinnamic acid (CHCA) matrix solution (6.2 mg/mL in 
36%/56%/8% methanol/ACN/water; Agilent Technologies UK Ltd, Stockport, 
UK). 
9. Ground steel MALDI target plates (Bruker UK). 
 
                                                          
1
 RPC18 Dynabeads are paramagnetic, non-porous particles modified with hydrophobic C18 
reversed phase chromatographic material. Other manufacturers and chromatographic materials can 
be used (e.g. C8 reversed phase, weak cation exchange, Cu
2+
-IMAC), but we have found that the 
RPC18 Dynabeads gave good yields in terms of the numbers and intensities of the peaks detected. 
3.1.3. MALDI-TOF MS data acquisition and analysis2 
1. Bruker Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker UK). 
2. Flexcontrol v2.0 software (Bruker UK)3. 
3. Peptide calibrant standard II and protein calibrant standard I (Bruker UK). 
4. ClinProTools v3.0 software (Bruker UK). 
 
3.1.4. Peptide Identification by LC-MS/MS 
1. Ultimate 3000 nano LC system coupled to an LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) via a 
PicoView nanospray source (New Objective Inc., Woburn, MA, USA).4 
2. C18 PepMap guard column (300 µm i.d. x 5 mm, 5 µm bead size, 100 Å pore 
size; LC Packings, Amsterdam, The Netherlands). 
3. C18 PepMap nano LC column (75 µm i.d. x 150 mm, 3 µm bead size, 100 Å 
pore size; LC Packings). 
4. Solvent A: 0.1% formic acid (FA) in HPLC grade water. 
5. Solvent B: 0.1% FA, 99.9% HPLC grade ACN (Rathburn Chemicals Ltd). 
6. Xcalibur v2.0 (Thermo Scientific) and Mascot Server v2.4 (Matrix Science Ltd, 
London, UK) software. 
7. Novex® Bolt™ Gel Electrophoresis System with pre-cast 10-20% gradient 
SDS-PAGE mini gels and running buffer (Life Technologies, Paisley, UK). 
8. InstantBlue colloidal Coomassie blue protein stain (Expedeon, Cambridge, 
UK). 
9. Siliconized Eppendorf tubes. 
10. SpeedVac. 
 
3.2. Methods 
3.2.1. Serum collection 
                                                          
2
 Other high-performance MALDI-TOF MS systems should be perfectly adequate, though might 
require additional data analysis software (cf. 3.2.3./3.2.4.). 
3
 Software versions higher (newer) than stated should also be adequate. 
4
 Other instrumentation and modes of operation can be used for peptide identification. 
1. Collect blood samples from consenting subjects by venepuncture into 8.5-mL 
BD Vacutainer® SST™ Advance tubes.5 
2. Gently invert tubes 5 times and allow the blood to clot at room temperature 
for 60 min. 
3. Centrifuge tubes at 2,200 rpm at 4ºC for 10 min and aliquot 200 L of serum 
supernatant into clearly labelled cryovials and freeze at -80°C until further 
use. Record date of sampling and freezing.  
 
3.2.2. Serum polypeptide extraction and sample preparation 
1. Thaw one 200-L aliquot of serum per subject/patient and distribute 50 L 
into three replicate 96-well Star PCR raised rim skirted plates. Change the 
location of samples across each replica plate. Also add 50 L of quality 
control (QC) serum at 6-12 random positions on each plate which are used to 
monitor assay reproducibility. Record all sample positions. Re-store plates at 
-80°C and run each plate on 3 separate days. 
2. Wash magnetic beads in 0.1% TFA solution and resuspend to a 
concentration of 50 mg/mL in an Eppendorf tube. 
3. Carry out the following steps on a Genesis Freedom 200 liquid-handling work 
station (or similar)6 except where indicated. 
4. Resuspend magnetic beads by pipetting up and down 10 times and transfer 5 
L to the wells of a 96-well plate containing the 50 L aliquots of serum. 
5. Mix by pipetting up and down 10 times and allow to stand for 1 min. 
6. Pull the beads to one side of the wells using the magnetic bead separator 
and allow beads to settle on the side for 30 sec. 
                                                          
5
 Blood collection requires informed consent from donors and studies require ethical approval from 
the relevant Committees on the Ethics of Human Research. Blood should be taken by a trained 
phlebotomist. Time of venepuncture should be recorded along with other subject/patient information 
relevant to the study, such as clinico-pathological features, treatment details, demographic data and 
any routine clinical assay results. Ideally, controls should be matched as closely as possible to cases. 
Ensure all samples are handled and processed identically (see Timms et al. 2010 for further 
information). 
6
 Other robotic liquid-handling platforms can be employed, although the protocol would need to be 
adjusted for other platforms. For example, a CyBi™-Disk liquid handling robot (CyBio AG, Jena, 
Germany) with pre-packed C4 and C18 ZipTips (Millipore, Watford, UK) was used successfully in 
previous work (Tiss et al. 2007) 
7. Remove the supernatant and discard. 
8. Add 200 L of wash solution (0.1% TFA) and pull the beads left to right 10 
times using the magnetic bead separator and then allow to settle on one side 
for 30 sec. 
9. Remove the wash solution and repeat the wash step. 
10. Spin the beads to the bottom of the wells by centrifugation at 2,000 g for 2 
min and remove remaining wash buffer. 
11. Add 7 L of elution solvent consisting of 50% ACN in 0.1% TFA and mix by 
pipetting up and down 10 times. Leave the mixture to stand for 30 sec. 
12. Transfer the 96-well plate to the magnetic bead separator and pull the beads 
to one side for 30 sec. 
13. Add 35 L of pre-prepared CHCA matrix solution to each well and mix by 
pipetting up and down 5 times. 
14. Spot volumes of 1 L of the eluate/matrix mix in quadruplicate onto a ground 
steel MALDI target plate and allow samples to dry at room temperature.7 This 
generates 12 spotting replicates per sample. 
 
3.2.3. MALDI-TOF MS data acquisition 
1. Externally calibrate the MALDI-TOF mass spectrometer8 in the linear positive 
ion mode using commercial peptide and protein calibration standards (in 
CHCA matrix) spotted onto the same target plate as the samples of interest. 
Use approximately 30 fmol of peptide and 500 fmol of protein standards per 
spot and use average masses for calibration. 
2. Set the following automated irradiation program and data quality filtering 
using FlexControl’s ‘AutoXecute’ function: each spectrum is the sum of 1,000 
laser shots per spotted sample delivered to 10 different locations on the spot 
in 10 sets of 100 shots (at a laser frequency of 10 Hz), after pre-irradiation 
                                                          
7
 Note that drying at relative humidity below ~30-40% has been reported to be detrimental for MALDI 
MS (Tiss et al. 2007). Thus, ensure that the relative humidity is ≥35-40%. 
8
 The Ultraflex II MALDI-TOF/TOF mass spectrometer is equipped with a 337 nm nitrogen laser, a 
gridless ion source, delayed-extraction (DE), a high-resolution timed ion selector and a 2 GHz 
digitizer. Other MALDI-TOF platforms can be used (see earlier footnote). 
with 10 shots at 5% higher laser power to improve spectral quality; set 
evaluation parameters so that only spectra (of 100 shots) containing at least 
one peak with a resolving power of greater than 300 and a signal-to-noise 
ratio (S/N) >10 in the m/z range of 700-4,000 are accumulated. 
3. Automatically acquire spectral profiles of the samples over a mass-to-charge 
(m/z) range of approximately 700-10,000 in the linear positive ion mode 
under 25 kV of ion acceleration, a delayed extraction (DE) potential 
difference of 1.4 kV, a lens potential of 5.9 kV and high gating strength to 
deflect ions below m/z 400. Apply DE (in our case at 80 ns) to give 
appropriate time-lag focusing after each laser shot. For signal detection, the 
detector gain is typically set to 7.5 and the sample rate to 2 GS/s. 
4. For further analysis, only include data for an individual serum sample when at 
least 3 of the 4 spotting replicates had 1,000 summed shots in at least 2 of 
the 3 run replicates. Typical averaged spectra for case control serum 
samples are shown in Figure 2 with ~300 aligned peaks detected across the 
dataset (S/N > 3.0). 
 
 Figure 2:  (A) Average MALDI-TOF MS spectra for case (dark grey) and control 
(light grey) serum samples over the full scan range of m/z 700-10,000.  (B) Zoomed 
MS spectra over the m/z range of 1,700-6,900. 
 
3.2.4. Spectral data analysis9 
1. Use ClinProTools v2.2 software for processing spectral data as follows: apply 
smoothing by averaging the intensities within a 5-point width moving window; 
apply baseline subtraction using an algorithm based on finding the lowest 
points between dominant local intensity maxima within a particular mass 
window; apply normalisation by dividing the intensity of each data point in a 
                                                          
9
 See footnote to section 3.1.3. 
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spectrum by the sum of all intensities in that spectrum; multiply intensities by 
a constant (e.g. 2 x 107) to give manageable output intensities; define peaks 
by identifying all local maxima in the spectra above a normalised intensity 
threshold of 0.2 and signal-to-noise ratio of 3; perform peak alignment to 
define common peaks using a mass window of 1,500 ppm. 
2. Determine average peak areas and standard deviations for QC serum 
samples and for each sample group (case, control etc.). All aligned peaks 
from the QC samples can be used to determine intra-plate and inter-plate 
assay reproducibility which should be within 10% and 20%, respectively (see 
Figure 3). 
3. Determine distribution of peak areas and apply appropriate test of 
significance to define peaks, which discriminate between sample groups. 
Apply correction for multiple testing. 
4. Split full dataset into training and test datasets. Construct multi-marker 
models (e.g. neural networks, support vector machines, genetic algorithms) 
from training data and determine classification performance on the test set, 
ideally in a blinded fashion.10 
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 Multi-marker model building and testing can be performed with the ClinProTools software. As 
before, other (classification) software can be used. 
 Figure 3:  Aligned MS spectra of QC serum replicates in pseudo-gel view (3 
replicate runs performed on different days with 12 samples per run each with 6 
spotting replicates, i.e. total of 216 spectra). Using all peaks, intra-assay variation 
was 6.2% ± 4.8 and inter-assay variation was 13.9% ± 7.6. 
 
3.2.5. Identification of MALDI-TOF peaks by LC-MS/MS11 
1. Prepare a fresh C18-extracted sample from 50 L of serum without adding 
matrix solution (see Section 3.2.2.; up to step 12). Using an Ultimate 3000 
LC system, inject 5 L of the extract from the autosampler onto a C18 
PepMap guard column and wash for 3 min with 100% solvent A at a flow rate 
of 25 µL/min. 
2. Switch to an analytical C18 PepMap nano LC column with 10% solvent B and 
apply a linear gradient of 10-50% B over 90 min, then to 100% B over 3 min. 
Continue with 100% B for 20 min and then reduce to 10% B over 0.5 min and 
continue for a further 20 min to re-equilibrate the column for the next injection. 
3. Operate the mass spectrometer (LTQ Orbitrap XL) in the data-dependent 
mode for automated switching between MS and MS/MS acquisition. Acquire 
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 See footnote to section 3.1.4. 
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S
p
e
c
tr
u
m
 n
u
m
b
e
r
survey full scan MS spectra (from m/z 400-2000) in the orbitrap with a 
resolution of 60,000 at m/z 400. Select the ‘top 6’ most intense ions for CID. 
Select a target ion value of 1 x 106 and maximum scan time of 500 ms for the 
survey full scan in the orbitrap. Select target ion values of 1 x 104 and a scan 
time setting 150 ms for CID. Dynamically exclude ions selected for MS/MS for 
60 sec. Enable the lock mass option for accurate mass measurement, using 
the polydimethylcyclosiloxane ion (m/z 455.120025) as an internal calibrant. 
4. Use initial precursor ion monitoring to identify masses matching the peaks of 
interest and then target these by mass and retention time in subsequent runs 
using high resolution MS/MS in the orbitrap. 
5. Process raw spectra using Mascot Distiller and search against the human 
UniProtKB database. For searching, select ‘no enzyme’, set MS tolerance to 
±10 ppm and MS/MS tolerance to 0.1 Da. Set oxidation (M), dehydration (N-
term C) and deamidation (NQ) as variable modifications. Also search data in 
the same way using the ‘de novo sequencing’ function of Mascot Distiller.12 
6. For larger peaks (m/z >5,000), dry down the extracted sample in a SpeedVac, 
resuspend in sample buffer and resolve on a 10-20% gradient mini gel 
following the manufacturer’s instructions. Stain the gel with InstantBlue and 
excise a gel piece in the molecular weight region of interest. 
7. Destain the gel piece by shaking at room temperature for 30 min in 200 L of 
50% methanol/10% acetic acid and then wash the gel piece in 100 L of 
100% ACN with shaking for 15 min. Extract polypeptides in 200 L of 50% 
formic acid, 25% ACN, 15% isopropanol by vigorous shaking for 2 hrs at 
room temperature. Centrifuge and recover the extract, dry down and 
resuspend in 0.1% formic acid. Analyse one fifth of this sample by MALDI-
TOF MS (see Section 3.2.3.), to verify the presence of peaks of interest. 
ZipTip the remaining sample and analyse by LC-MS/MS as described above 
in this section, starting with the first step. 
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 If the identity of the peak of interest is still ambiguous, it may be necessary to carry out 
fractionation of the scaled-up extract. For a detailed protocol refer to (Tiss et al. 2010). 
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